Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC.
Coates LC, Garrood T, Gullick N, Helliwell P, Kent T, Marks J, Tillett W, Kaur-Papadakis D, Tahir H, van Haaren S, McInnes I. Coates LC, et al. Among authors: gullick n. Rheumatology (Oxford). 2022 Dec 23;62(1):e1-e3. doi: 10.1093/rheumatology/keac388. Rheumatology (Oxford). 2022. PMID: 35799375 Free article. No abstract available.
Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope.
Tillett W, Allen A, Tucker L, Chandler D, Ciurtin C, Davis C, Dick A, Foulkes A, Gullick N, Helliwell P, Jadon D, Jones G, Kyle S, Madhok V, McHugh N, Parkinson A, Raine T, Siebert S, Smith C, Coates LC. Tillett W, et al. Among authors: gullick n. Rheumatology (Oxford). 2021 Apr 6;60(4):1588-1592. doi: 10.1093/rheumatology/keaa526. Rheumatology (Oxford). 2021. PMID: 33097948
Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis-study protocol for the MONITOR-PsA study, a trials within cohorts study design.
Rombach I, Tillett W, Jadon D, Tucker L, Watson M, Francis A, Sinomati Y, Eldridge L, Dritsaki M, Dutton SJ, Al-Mossawi H, Gullick N, Thompson B, Coates LC. Rombach I, et al. Among authors: gullick n. Trials. 2021 Mar 4;22(1):185. doi: 10.1186/s13063-021-05142-7. Trials. 2021. PMID: 33663566 Free PMC article.
Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs.
Tucker L, Allen A, Chandler D, Ciurtin C, Dick A, Foulkes A, Gullick N, Helliwell P, Jadon D, Jones G, Kyle S, Madhok V, McHugh N, Parkinson A, Raine T, Siebert S, Smith C, Tillett W, Coates LC. Tucker L, et al. Among authors: gullick n. Rheumatology (Oxford). 2022 Aug 30;61(9):3514-3520. doi: 10.1093/rheumatology/keac260. Rheumatology (Oxford). 2022. PMID: 35640653 No abstract available.
The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs.
Tucker L, Allen A, Chandler D, Ciurtin C, Dick A, Foulkes A, Gullick N, Helliwell P, Jadon D, Jones G, Kyle S, Madhok V, McHugh N, Parkinson A, Raine T, Siebert S, Smith C, Tillett W, Coates LC. Tucker L, et al. Among authors: gullick n. Rheumatology (Oxford). 2022 Aug 30;61(9):e255-e266. doi: 10.1093/rheumatology/keac295. Rheumatology (Oxford). 2022. PMID: 35640657 No abstract available.
48 results